Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 12/20 | 0.58 |
| ▸ | HSD17B1 | P14061 | 10/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157668 | 0.90 | HSD17B2 (0.49) | HSD17B2HSD17B1CYP3A4ALDH1A1KDM4E | |
| SCHEMBL2157975 | 0.86 | HSD17B1 (0.45) | HSD17B2HSD17B1ALDH1A1TP53TDP1 | |
| SCHEMBL2157826 | 0.86 | KDM1A (0.48) | HSD17B2HSD17B1ALDH1A1TP53TDP1 | |
| SCHEMBL2158472 | 0.86 | HSD17B1 (0.45) | HSD17B2HSD17B1ALDH1A1TP53TDP1 | |
| SCHEMBL2157562 | 0.84 | HSD17B1 (0.52) | HSD17B2HSD17B1CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL12464422 | 0.84 | ALDH1A1 (0.54) | HSD17B2HSD17B1ALDH1A1TP53TDP1 | |
| SCHEMBL2158979 | 0.84 | LMNA (0.47) | HSD17B2HSD17B1ALDH1A1LMNAHTT | |
| SCHEMBL2158359 | 0.83 | MAPT (0.45) | HSD17B2HSD17B1ALDH1A1HTTTP53 | |
| SCHEMBL2157979 | 0.83 | KDM1A (0.59) | ALDH1A1TP53TDP1IDH1 | |
| SCHEMBL2157786 | 0.83 | KDM1A (0.45) | HSD17B2HSD17B1CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985769-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-06-29 | — | — | US | disclosed |
| US-6881741-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | HAVCR2, ZC3HAV1, MAVS | HSD17B2 1131/4885HSD17B1 740/4885CYP3A4 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.